UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

British journal of cancer, 2013-10, Vol.109 (7), p.1735-1743

2013

Volltextzugriff (PDF)

Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands

International journal of colorectal disease, 2014-10, Vol.29 (10), p.1203-1210

2014

Volltextzugriff (PDF)

Single-mode waveguides for GRAVITY

Astronomy and astrophysics (Berlin), 2018-06, Vol.614

2018

Volltextzugriff (PDF)

Cabazitaxel In Second Line (2l) Treatment Of Metastatic Castration Resistant Prostate Cancer : An Economic Evaluation In Sweden

Value in health, 2013-05, Vol.16 (3), p.A138-A138

2013

Volltextzugriff (PDF)

PRM113 Development of a Generic Spanish Version of the Modified Myelofibrosis Symptom Assessment Form (MFSAF) Diary

Value in health, 2012-11, Vol.15 (7), p.A481-A481

2012

Volltextzugriff (PDF)

Aflibercept + FOLFIRI (AF) Versus. Placebo + FOLFIRI (PF) in Metastatic Colorectal Cancer (mCRC): Mean Overall Survival (OS) in a “Better Responders” Patient Population of the Velour Trial

Value in health, 2013-11, Vol.16 (7), p.A397-A398

2013

Volltextzugriff (PDF)

Quality of Life in Patients with Metastatic Colorectal Cancer (mCRC): A Utilities Study in the United Kingdom and the Netherlands

Value in health, 2013-11, Vol.16 (7), p.A420-A420

2013

Volltextzugriff (PDF)

PRM86 Utilizing Indirect Treatment Comparisons in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Value in health, 2012-11, Vol.15 (7), p.A475-A476

2012

Volltextzugriff (PDF)

Second-Line Treatment of Metastatic Colorectal Cancer (mCRC): A Systematic Literature Review (SLR) and Feasibility Assessment of Conducting Indirect Treatment Comparison (ITC) Analysis

Value in health, 2013-11, Vol.16 (7), p.A395-A396

2013

Volltextzugriff (PDF)

EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective

Value in health, 2024-06, Vol.27 (6), p.S125-S125

2024

Volltextzugriff (PDF)

All-fiber-coupled mid-infrared quartz-enhanced photoacoustic sensors

Optics and laser technology, 2024-09, Vol.176, p.110926, Article 110926

2024

Volltextzugriff (PDF)

PCN128 EQ-5D Utility Index in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Progression During or After First-Line Docetaxel Therapy

Value in health, 2011, Vol.14 (7), p.A457-A458

2011

Volltextzugriff (PDF)

PRM58 - IMPACT OF FUTURE COSTS IN COST-EFFECTIVENESS ANALYSES AND A COMPARISON OF DIRECT AND INDIRECT METHODS USING MODELS OF CABAZITAXEL IN PROSTATE CANCER AND CLOPIDOGREL IN ACUTE CORONARY SYNDROME

Value in health, 2018-10, Vol.21, p.S365-S365

2018

Volltextzugriff (PDF)

Single-mode waveguides for GRAVITY: II. Single-mode fibers and Fiber Control Unit

Astronomy and astrophysics (Berlin), 2024-01, Vol.681, p.A26

2024

Volltextzugriff (PDF)

Modeling the population health benefits of LDL-C reduction with alirocumab among cardiovascular disease/heterozygous familial hypercholesterolemia patients with elevated LDL-C

Atherosclerosis, 2018-08, Vol.275, p.e100-e100

2018

Volltextzugriff (PDF)

MODELING THE IMPACT OF ALIROCUMAB TREATMENT DELAY ON 3-YEAR CARDIOVASCULAR EVENT RISK

Value in health, 2017-05, Vol.20 (5), p.A270

2017

Volltextzugriff (PDF)

Single-mode waveguides for GRAVITY: I. The cryogenic 4-telescope integrated optics beam combiner

Astronomy and astrophysics (Berlin), 2018-06, Vol.614, p.A70

2018

Volltextzugriff (PDF)

PCV139 - Patient Utility Estimates In Patients At High Cardiovascular Risk

Value in health, 2015-11, Vol.18 (7), p.A398-A398

2015

Volltextzugriff (PDF)

Patient Utility Estimates In Patients At High Cardiovascular Risk

Value in health, 2015-11, Vol.18 (7), p.A398-A398

2015

Volltextzugriff (PDF)

PCN61 - Cabazitaxel In Second Line (2l) Treatment Of Metastatic Castration Resistant Prostate Cancer : An Economic Evaluation In Sweden

Value in health, 2013-05, Vol.16 (3), p.A138-A138

2013

Volltextzugriff (PDF)

PCN33 - Aflibercept + FOLFIRI (AF) Versus. Placebo + FOLFIRI (PF) in Metastatic Colorectal Cancer (mCRC): Mean Overall Survival (OS) in a “Better Responders” Patient Population of the Velour Trial

Value in health, 2013-11, Vol.16 (7), p.A397-A398

2013

Volltextzugriff (PDF)

Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.128-128

2011

Volltextzugriff (PDF)

PCV53 - Cardiovascular Event Rates in a High-Risk General Population Cohort of 340,000 Individuals in the United Kingdom

Value in health, 2015-11, Vol.18 (7), p.A382-A383

2015

Volltextzugriff (PDF)

633 - Aflibercept/Folfiri (AF) VS Placebo/Folfiri (PF) In Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis of Survival Excluding Adjuvant (ADJ)-Only Patients in the Velour Trial

Annals of oncology, 2012-09, Vol.23, p.ix214-ix214

2012

Volltextzugriff (PDF)

Aflibercept/Folfiri (AF) VS Placebo/Folfiri (PF) In Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis of Survival Excluding Adjuvant (ADJ)-Only Patients in the Velour Trial

Annals of oncology, 2012-09, Vol.23, p.ix214

2012

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(79)

Publikationsform

Artikel
(88)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Physical Sciences
(21)
Physics
(19)
Life Sciences & Biomedicine
(18)
Chemistry
(10)
Humans
(10)
Internal Medicine
(10)
Biological And Medical Sciences
(9)
Exact Sciences And Technology
(9)
Optics
(9)
Engineering Sciences
(8)
Technology
(8)
Food Science & Technology
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)
Mechanics
(7)
Chemistry, Applied
(6)
Materials Science
(6)
Thermics
(6)
Concanavalin A - Pharmacology
(5)
Quantitative Analysis
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands

Single-mode waveguides for GRAVITY

Cabazitaxel In Second Line (2l) Treatment Of Metastatic Castration Resistant Prostate Cancer : An Economic Evaluation In Sweden

PRM113 Development of a Generic Spanish Version of the Modified Myelofibrosis Symptom Assessment Form (MFSAF) Diary

Aflibercept + FOLFIRI (AF) Versus. Placebo + FOLFIRI (PF) in Metastatic Colorectal Cancer (mCRC): Mean Overall Survival (OS) in a “Better Responders” Patient Population of the Velour Trial

Quality of Life in Patients with Metastatic Colorectal Cancer (mCRC): A Utilities Study in the United Kingdom and the Netherlands

PRM86 Utilizing Indirect Treatment Comparisons in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Second-Line Treatment of Metastatic Colorectal Cancer (mCRC): A Systematic Literature Review (SLR) and Feasibility Assessment of Conducting Indirect Treatment Comparison (ITC) Analysis

EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective

All-fiber-coupled mid-infrared quartz-enhanced photoacoustic sensors

PCN128 EQ-5D Utility Index in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Progression During or After First-Line Docetaxel Therapy

PRM58 - IMPACT OF FUTURE COSTS IN COST-EFFECTIVENESS ANALYSES AND A COMPARISON OF DIRECT AND INDIRECT METHODS USING MODELS OF CABAZITAXEL IN PROSTATE CANCER AND CLOPIDOGREL IN ACUTE CORONARY SYNDROME

Single-mode waveguides for GRAVITY: II. Single-mode fibers and Fiber Control Unit

Modeling the population health benefits of LDL-C reduction with alirocumab among cardiovascular disease/heterozygous familial hypercholesterolemia patients with elevated LDL-C

MODELING THE IMPACT OF ALIROCUMAB TREATMENT DELAY ON 3-YEAR CARDIOVASCULAR EVENT RISK

Single-mode waveguides for GRAVITY: I. The cryogenic 4-telescope integrated optics beam combiner

PCV139 - Patient Utility Estimates In Patients At High Cardiovascular Risk

Patient Utility Estimates In Patients At High Cardiovascular Risk

PCN61 - Cabazitaxel In Second Line (2l) Treatment Of Metastatic Castration Resistant Prostate Cancer : An Economic Evaluation In Sweden

PCN33 - Aflibercept + FOLFIRI (AF) Versus. Placebo + FOLFIRI (PF) in Metastatic Colorectal Cancer (mCRC): Mean Overall Survival (OS) in a “Better Responders” Patient Population of the Velour Trial

Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC)

PCV53 - Cardiovascular Event Rates in a High-Risk General Population Cohort of 340,000 Individuals in the United Kingdom

633 - Aflibercept/Folfiri (AF) VS Placebo/Folfiri (PF) In Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis of Survival Excluding Adjuvant (ADJ)-Only Patients in the Velour Trial

Aflibercept/Folfiri (AF) VS Placebo/Folfiri (PF) In Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis of Survival Excluding Adjuvant (ADJ)-Only Patients in the Velour Trial

Suchergebnisse filtern